The former targets FLT3 (FMS like tyrosine kinase-3) to treat acute myelogenous leukemia (AML), while the latter targets HER-2 (human epidermal growth factor receptor 2)-expressing cancers, such as breast and gastric neoplasms. The gene discussed is FLT3; the disease is cancer.